Literature DB >> 15942942

PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements.

Bruce Poppe1, Pascale De Paepe, Lucienne Michaux, Nicole Dastugue, Christian Bastard, Christian Herens, Els Moreau, Francesco Cavazzini, Nurten Yigit, Heidi Van Limbergen, Anne De Paepe, Marleen Praet, Chris De Wolf-Peeters, Iwona Wlodarska, Frank Speleman.   

Abstract

We present an extensive characterization of 10 B-cell lymphomas with a t(9;14)(p13;q32). The presence of the PAX5/IGH gene rearrangement was demonstrated by fluorescence in situ hybridization (FISH) using a validated probe set, whereas complex karyotypic changes were reassessed by multiplex-FISH (M-FISH). Pathologic and clinical review revealed the presence of this rearrangement in 4 histiocyte-rich, T-cell-rich B-cell lymphomas (HRTR-BCLs) and 2 posttransplantation diffuse large B-cell lymphomas (PTLD-DLBCLs). In contrast to initial observations describing this translocation in lymphoplasmacytic lymphoma (LPL) and LPL-derived large B-cell lymphoma, our data showed a wide morphologic and clinical spectrum associated with the PAX5/IGH rearrangement, pointing to an association between this aberration and a subset of de novo DLBCLs presenting with advanced disease and adverse prognosis. In addition, the recurrent incidence of this rearrangement in both HRTR-BCL (4 cases) and PTLD-DLBCL (2 cases) was previously unrecognized and is intriguing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942942     DOI: 10.1002/gcc.20214

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Epstein-Barr virus-positive diffuse large B-cell lymphoma carrying a t(9;14)(p13;q32) translocation.

Authors:  Hitoshi Ohno; Momoko Nishikori; Hironori Haga; Kotaro Isoda
Journal:  Int J Hematol       Date:  2009-05-12       Impact factor: 2.490

2.  PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).

Authors:  Kazuyuki Sato; Hirotaka Sakai; Masayuki Kato; Yuji Nishio; Yuka Tsuruoka; Yu Uemura; Satoshi Yokoi; Tasuku Saito; Manabu Matsunawa; Yoshinori Suzuki; Yasushi Isobe; Yasuyuki Inoue; Masatomo Takahashi; Ikuo Miura
Journal:  Int J Hematol       Date:  2015-01-30       Impact factor: 2.490

3.  CD4-positive diffuse large B cell lymphoma identified by flow cytometry: two case reports.

Authors:  Marisa Arrondini; Antonella Barreca; Sabrina Aliberti; Anna Demurtas; Fabrizio Tondat; Domenico Novero; Alessandra Stacchini
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

4.  CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.

Authors:  Elaine Y Chung; James N Psathas; Duonan Yu; Yimei Li; Mitchell J Weiss; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2012-05-01       Impact factor: 14.808

5.  Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.

Authors:  Stefan D Dojcinov; Girish Venkataraman; Stefania Pittaluga; Iwona Wlodarska; Jeffrey A Schrager; Mark Raffeld; Robert K Hills; Elaine S Jaffe
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

6.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

7.  A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma.

Authors:  Hakim Bouamar; Saman Abbas; An-Ping Lin; Long Wang; Daifeng Jiang; Kenneth N Holder; Marsha C Kinney; Scott Hunicke-Smith; Ricardo C T Aguiar
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

8.  PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.

Authors:  Rajani Kanteti; Vidya Nallasura; Sivakumar Loganathan; Maria Tretiakova; Todd Kroll; Soundararajan Krishnaswamy; Leonardo Faoro; Philip Cagle; Aliya N Husain; Everett E Vokes; Deborah Lang; Ravi Salgia
Journal:  Lab Invest       Date:  2009-01-12       Impact factor: 5.662

9.  Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Authors:  S Kasar; C Underbayev; Y Yuan; M Hanlon; S Aly; H Khan; V Chang; M Batish; T Gavrilova; F Badiane; H Degheidy; G Marti; E Raveche
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

Review 10.  Pax genes in embryogenesis and oncogenesis.

Authors:  Qiuyu Wang; Wen-Hui Fang; Jerzy Krupinski; Shant Kumar; Mark Slevin; Patricia Kumar
Journal:  J Cell Mol Med       Date:  2008-07-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.